Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra L Guerrero-Rodríguez

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Frontiers in Cell and Developmental Biology|December 26, 2022
Role of CD36 in cancer progression, stemness, and targetingSandra L Guerrero-Rodríguez, Cecilia Mata-Cruz, Sonia M Pérez-Tapia, et al.
Frontiers in Immunology|February 19, 2025
Discovery and <i>in vitro</i> characterization of a human anti-CD36 scFvCecilia Mata-Cruz, Sandra L Guerrero-Rodríguez, Keyla Gómez-Castellano, et al.
Technology in Cancer Research & Treatment|August 22, 2019
Gpn3 Is Essential for Cell Proliferation of Breast Cancer Cells Independent of Their Malignancy DegreeBárbara Lara-Chacón, Sandra L Guerrero-Rodríguez, Karla J Ramírez-Hernández, et al.
Chemical Biology & Drug Design|November 21, 2025
Identification of New CD36 Antagonists by Structure-Based Virtual ScreeningSandra L Guerrero-Rodríguez, Luis Córdova-Bahena, Fabiola Cortés-Mendoza, et al.
Pharmacological Reports : PR|April 27, 2019
Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drugLuz X Vásquez-Bochm, Mireya Velázquez-Paniagua, Sandra S Castro-Vázquez, et al.
Oncotarget|March 25, 2016
Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cellsCharmina Aguirre-Alvarado, Aldo Segura-Cabrera, Inés Velázquez-Quesada, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Frontiers in Cell and Developmental Biology|December 26, 2022
Role of CD36 in cancer progression, stemness, and targetingSandra L Guerrero-Rodríguez, Cecilia Mata-Cruz, Sonia M Pérez-Tapia, et al.
Frontiers in Immunology|February 19, 2025
Discovery and <i>in vitro</i> characterization of a human anti-CD36 scFvCecilia Mata-Cruz, Sandra L Guerrero-Rodríguez, Keyla Gómez-Castellano, et al.
Technology in Cancer Research & Treatment|August 22, 2019
Gpn3 Is Essential for Cell Proliferation of Breast Cancer Cells Independent of Their Malignancy DegreeBárbara Lara-Chacón, Sandra L Guerrero-Rodríguez, Karla J Ramírez-Hernández, et al.
Chemical Biology & Drug Design|November 21, 2025
Identification of New CD36 Antagonists by Structure-Based Virtual ScreeningSandra L Guerrero-Rodríguez, Luis Córdova-Bahena, Fabiola Cortés-Mendoza, et al.
Pharmacological Reports : PR|April 27, 2019
Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drugLuz X Vásquez-Bochm, Mireya Velázquez-Paniagua, Sandra S Castro-Vázquez, et al.
Oncotarget|March 25, 2016
Virtual screening-driven repositioning of etoposide as CD44 antagonist in breast cancer cellsCharmina Aguirre-Alvarado, Aldo Segura-Cabrera, Inés Velázquez-Quesada, et al.
Pageof 1